Heron Therapeutics, Inc. /De/ (HRTX) Stock Price & Analysis

Heron Therapeutics, Inc. /De/ (HRTX) rose 4.21% to USD 0.34 as of September 8, 2026 at 06:22 UTC, according to Nexqual real-time market data.

HRTX last closed at USD 0.34; the session ranged USD 0.33–0.36 on volume of 1,878,452 shares. Market capitalization is —, with a 52-week range of USD 0.3–1.58 (NCM). Source: Nexqual, September 8, 2026 at 06:22 UTC.

Key Statistics (as of September 8, 2026 at 06:22 UTC)

Technical Analysis (HRTX)

Nexqual's technical model rates HRTX "SELL" based on 1 bullish and 4 bearish signals across 128 daily candles, as of September 8, 2026 at 06:22 UTC.

From Heron Therapeutics, Inc. /De/'s Latest SEC 10-K Filing (filed 2026-02-26)

Key Strengths & Strategy (as disclosed to the SEC)

• The FDA has various programs, including Breakthrough Therapy, Fast Track and Priority Review, which are intended to expedite or simplify the process for reviewing drug candidates, and/or provide for approval based on surrogate endpoints.
• Biochronomer Technology Our proprietary Biochronomer Technology is designed to deliver therapeutic levels of a wide range of otherwise short-acting pharmacological agents over a period from days to weeks with a single administration.
• We maintain confidentiality agreements with potential and existing manufacturers in order to protect our proprietary rights related to our Products and our Biochronomer Technology. 7   Some of the critical materials and components used in manufacturing our Products are sourced from single suppliers.
• Intellectual Property Our success will depend in large part on our ability to:   • obtain and maintain international and domestic patents and other legal protections for the proprietary technology, inventions and improvements we consider important to our business;   • prosecute and defend our patents;   • preserve our trade secrets; and   • operate without infringing the patents and proprietary rights of other parties.

Partnerships

• In January 2024, we entered into a co-promotion agreement with Crosslink Network to expand the sales network supporting ZYNRELEF.

Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.

Peers & Related Stocks

Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: September 8, 2026 at 06:22 UTC. This page is informational and not investment advice.